Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study.
Juan Luis Rodríguez HermosaGianna Vargas CentanaroMaría Estela González CastroMarc MiravitllesLourdes Lázaro-AseguradoBeatriz María Jiménez-RodríguezRosanel Amaro RodríguezRosaly Moreno MéndezMaría Torres-DuranJosé Maria Hernández PérezAna María Humanes NavarroMyriam CallePublished in: Biomedicines (2023)
These observations suggest that patients with AATD should be considered at a higher risk of developing severe COVID-19. Further studies are needed on the role of A1AT in the prognosis of SARS-CoV-2 infection and its possible therapeutic role.